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RESEARCH ARTICLE Open Access
Metabolic dysregulation and cancer
mortality in a national cohort of blacks and
whites
Tomi Akinyemiju1,2,3*, Justin Xavier Moore1,2,4, Suzanne Judd5, Susan Lakoski6, Michael Goodman7,
Monika M. Safford8,9 and Maria Pisu2,9
Abstract
Background: We examined the association between metabolic dysregulation and cancer mortality in a prospective
cohort of Black and White adults.
Methods: A total of 25,038 Black and White adults were included in the analysis. Metabolic dysregulation was defined
in two ways: 1) using the joint harmonized criteria for metabolic syndrome (MetS) and 2) based on factor analysis of 15
variables characterizing metabolic dysregulation. We estimated hazards ratios (HRs) and 95% confidence intervals (CIs)
for the association of MetS and metabolic dysregulation with cancer mortality during follow-up using Cox proportional
hazards models.
Results: About 46% of Black and 39% of White participants met the criteria for MetS. Overall, participants with
MetS (HR: 1.22, 95% CI: 1.03–1.45) were at increased risk of cancer-related death. In race-stratified analysis, Black
participants with MetS had significantly increased risk of cancer mortality compared with those without MetS (HR:
1.32, 95% CI: 1.01–1.72), increasing to more than a 2-fold risk of cancer mortality among those with
five metabolic syndrome components (HR: 2.35, 95% CI: 1.01–5.51).
Conclusions: There are marked racial differences in the prevalence of metabolic dysregulation defined as
MetS based on the harmonized criteria. The strong positive associations between MetS and cancer mortality
suggests that efforts to improve cancer outcomes in general, and racial disparities in cancer outcomes
specifically, may benefit from prevention and management of MetS and its components.
Keywords: Metabolic syndrome, Cancer, Racial disparities, Cancer mortality, Survival
Background
Significant racial disparities in cancer mortality have been
well documented in the United States (US), with at least a
13% difference in 5-year survival observed between Blacks
and Whites diagnosed with breast and colorectal cancer
[1]. Black adults are more likely to develop metabolic dys-
regulation and meet the formal criteria for metabolic syn-
drome (MetS). MetS is a cluster of interrelated
biochemical abnormalities that include central obesity, in-
sulin resistance, dyslipidemia and hypertension, and has
been shown to significantly increase the risk of coronary
heart disease, stroke and type-2 diabetes [2–5]. Individual
components of MetS, specifically obesity [6, 7], diabetes
[8], and hypertension [9, 10], have been associated with in-
creased risk for cancer; however, the entire cluster of MetS
components has only more recently been shown to be as-
sociated with cancer risk and outcome.
Several studies show a significant and independent
positive association between MetS and cancer incidence
[11–13], distant metastasis [14] and aggressive cancer
phenotypes [15–17]. A recent systematic review and
meta-analysis of 43 studies found significant associations
between MetS and risk of liver cancer, colorectal cancer,
and bladder cancer [18]. Importantly, the association be-
tween MetS and cancer risk has consistently been found
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to be larger than the corresponding associations for indi-
vidual MetS components, suggesting that there may be
independent, complex biological processes underlying
this association. However, despite renewed interest in
the role of MetS in cancer etiology and outcomes, many
of the prior studies have suffered from significant lead-
time, length and selection biases, with only a few studies
examining racial differences in this association. Few pro-
spective studies have examined objective measures of
MetS at baseline in relation to cancer mortality, with ra-
cially diverse study populations to assess race-specific
risk. Furthermore, although there is growing consensus
regarding the biological importance of MetS, questions
remain about the clinical definition, categorical cut-
points and included components, especially in relation
to cancer risk. In this study, we assess MetS and vari-
ables associated with metabolic dysregulation at baseline
among Blacks and Whites, and examine the association
with cancer mortality during follow-up.
This study takes advantage of the large REasons for
Geographic and Racial Differences in Stroke (REGARDS)
cohort, with individual assessment of MetS components
at baseline, and cancer mortality identified prospectively
during follow-up. The objective of the current study was
to determine the association between MetS and metabolic
dysregulation with cancer mortality among Black and
White adults in the US.
Methods
Data source
REGARDS is one of the largest ongoing national longi-
tudinal cohorts of community-dwelling adults in the US
[19]. Designed to examine factors contributing to racial
and geographic differences in stroke mortality, the
REGARDS study includes 30,239 participants ages
45 years and older at baseline; 45% male, 41% Black, and
69% >60 years old [19]. REGARDS participants were
randomly sampled from all US states and recruited via
mail and telephone. REGARDS was originally designed
to evaluate risk factors and racial disparities in stroke,
therefore 30% of participants were recruited from the
‘Stroke Belt’ (Alabama, Arkansas, Georgia, Louisiana,
Mississippi, North Carolina, South Carolina, and Ten-
nessee), 20% from the ‘Stroke Buckle’ (Georgia, North
Carolina, and South Carolina) and approximately 50%
from other US states. Participants were recruited be-
tween January 2003 and October 2007, and detailed
information about demographics, health behaviors,
chronic medical conditions, physical status, diet, and
medications were collected. In addition, baseline in-
home visits were scheduled for all enrolled patients, dur-
ing which anthropometric data including body weight,
waist circumference, height, and blood pressure were
obtained. Participants were asked to fast overnight for
10–12 h before visitation and to have medications avail-
able during the time of visitation. Trained technicians
collected blood and urine samples and assessed current
medication use. Participants were subsequently con-
tacted by telephone every 6-months to identify medical
events or hospitalizations experienced since the prior
contact. Medical events or deaths were ascertained using
death certificates, medical records, and/or interviewed
proxies to determine causes of the death.
Main exposure variables
We defined MetS based on the recently published con-
sensus statement developed by multiple health and pro-
fessional organizations [20]. The joint harmonized
criteria by Alberti et al. defined MetS as the presence of
at least three of: 1) Diabetes: fasting glucose ≥126 mg
per liter (mg/L) (or a glucose ≥200 mg/L for those not
fasting) or the use of insulin or oral hypoglycemic
agents; 2) High triglycerides: triglycerides ≥150 mg per
deciliter (mg/dL) or reported use of medication for ele-
vated triglycerides; 3) Dyslipidemia: low high-density
lipoprotein (HDL) cholesterol <40 mg/dL for males and
<50 mg/dL for females, or use of lipid lowering medica-
tions; 4) Hypertension: systolic blood pressure ≥
140 mmHg, diastolic blood pressure ≥ 90 mmHg, or the
reported use of antihypertensive agents; and 5) Obesity:
increased waist circumference (WC) >102 cm for males
or >88 cm for females.
Secondary exposure variable
We additionally defined metabolic dysregulation based
on factor analysis of 15 metabolic related variables
(height, weight, WC, body mass index (BMI), log of
triglycerides, cholesterol, HDL cholesterol, log of low-
density lipoprotein (LDL) cholesterol, dyslipidemia, sys-
tolic blood pressure, diastolic blood pressure, hyperten-
sion, log of insulin, glucose, and diabetes). We used
orthogonal rotation of each component in the factor
analysis, examined the scree plots and employed an
eigenvalue cut-point of approximately 1.0 for inclusion
of final derived factors. We calculated final factor load-
ings of 6 factors based on the full sample, and presented
results only for factors with absolute values for loadings
>0.4. We named patterns based on the factor loadings
that contributed most highly to each pattern (Additional
file 1). For instance, Factor 1 was termed “Obesity” since
it was loaded heavily by variables associated with body
weight such as weight (0.91), waist circumference (0.86),
BMI (0.94), and log insulin (0.61). Similarly, Factor 4
was termed “Lipids” since it was loaded heavily by log
triglycerides (0.76), HDL cholesterol (−0.69), and dyslip-
idemia (0.70).
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Cancer mortality
Cancer mortality was identified through semi-annual tele-
phone follow-up, death information from participant
proxies, linkages with the Social Security Death Index
(SSDI) as well as the National Death Index (NDI). Date of
death was confirmed using death certificates, SSDI and/or
NDI, and cause of death was adjudicated by a committee
of experts using all available information as recommended
by national guidelines [21]. Follow-up data for this analysis
was available through December 31, 2012.
Participant characteristics
Demographic information used for analysis included age,
race, gender, income, education, and geographic location.
Health behaviors included tobacco and alcohol use.
Chronic medical conditions assessed included: atrial fibril-
lation, chronic lung disease, chronic kidney disease, cor-
onary artery disease, deep vein thrombosis, diabetes,
dyslipidemia, hypertension, myocardial infarction, obesity,
peripheral artery disease, and stroke. In addition, we in-
cluded serum high-sensitivity C-reactive protein (hsCRP)
as a covariate, since multiple studies have demonstrated
racial differences in CRP [22–24].
Statistical analysis
We compared baseline characteristics by race using chi-
square tests for categorical characteristics, analysis of vari-
ance (ANOVA) for continuous variables, and Kruskal-Wallis
test for non-normal continuous variables. We categorized
each metabolic factor into quartiles based on the distribution
among study participants, with the highest quartile corre-
sponding to participants at the highest distribution of the
factor. Thus, participants in the fourth quartile of the choles-
terol factor had the highest mean cholesterol levels in the
study. To estimate the hazards of cancer mortality, we fit
Cox proportional hazard models examining each MetS com-
ponent independently and jointly in relation to cancer mor-
tality. We a priori specified examination of race-stratified
models, and stratified statistical models by race groups after
adjusting for socio-demographics, health behaviors, baseline
medical conditions, and hs-CRP. In sensitivity analysis we
adjusted models for socio-demographics and health behav-
iors. The results of all models were expressed as adjusted
hazard ratios (AHR) and the corresponding 95% confidence
intervals (CI). Individuals were censored at the time of death,
loss to follow-up, or the end of cancer mortality ascertain-
ment (December 31, 2012). SAS version 9.4 and STATA ver-
sion 13 were used for all statistical analysis. We considered
two-sided p values <0.05 as statistically significant.
Results
Cohort characteristics
Among 30,239 REGARDS participants, 5201 were excluded
due to missing data for exposure (components of metabolic
syndrome) or follow-up time, resulting in 25,038 participants
remaining for the main analysis (Fig. 1). The most common
cancer deaths were lung (27.5%), gastro-intestinal (20.6%),
and hematological (10.6%) (Additional file 1). As shown in
Table 1, Black participants were younger (63.8 vs. 65.3 years),
less likely to be male (37.9% vs. 49.9%), had lower education
(19.0% vs. 7.1% with less than high school education), and
lower income (25.6% vs. 11.8% with less than $20,000 house-
hold income) compared with White participants (p values
<0.01). Compared with White participants, Black partici-
pants had higher total body weight (87.7 vs. 82.4 kg), WC
Fig. 1 Study flowchart and breakdown of study participants used in analyses
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(97.9 vs. 94.8 cm), BMI (30.7 vs. 28.3 kg per meter squared
[kg/m2]), and LDL-cholesterol (115.0 vs. 110.0 mg/dL),
but had lower levels of triglycerides (95.0 vs. 122 mg/dL),
(p values <0.01). Although Black participants were less
likely to have dyslipidemia (54.6% vs. 61.5%, p value <
0.02), they were more likely to have hypertension (71.0%
vs. 50.3%) and diabetes (29.4% vs. 16.2%) compared with
White participants (p value <0.01). The formal criteria
for MetS was met among 45.8% of Black participants and
38.8% of White participants (p value <0.01).
Metabolic syndrome and cancer mortality
Among all participants (Table 2), those with MetS were at
increased risk of cancer mortality compared with those
without MetS (AHR: 1.22; 95% CI: 1.03–1.45). The risk of
cancer-related deaths increased with the number of MetS
components; participants with three (AHR: 1.41, 95% CI:
1.01–1.97), four (AHR: 1.62, 95% CI: 1.12–2.34) or five
(AHR: 1.59, 95% CI: 1.01–2.51) components experienced
significantly increased risk of cancer mortality (Table 2;
Fig. 2) compared with participants with none. Black
Table 1 Baseline characteristics of REGARDS participants by race (N = 25,038)
Black
(N = 9822)
White
(N = 15,216)
p valuea
Ageb 63.8 (9.3) 65.3 (9.4) <0.01
Male Gender (%) 3721 (37.9) 7588 (49.9) <0.01
≤ High School Education (%) 1864 (19.0) 1086 (7.1) <0.01
≤ $20,000 Income (%) 2511 (25.6) 1796 (11.8) <0.01
High WC/ Obesity
Weight (kg)b 87.7 (20.1) 82.4 (18.9) <0.01
Height (in.)b 66.4 (4.3) 67.0 (4.0) <0.01
WC (cm)b 97.9 (15.2) 94.8 (15.5) <0.01
BMIb 30.7 (6.7) 28.3 (5.6) <0.01
Elevated Triglycerides
Triglycerides (mg/dL)c 95.0 (72.0–130.0) 122.0 (88.0–174.0) <0.01
Total Cholesterol (mg/dL)b 193.3 (40.9) 192.0 (39.5) 0.01
LDL-Cholesterol (mg/dL)c 115.0 (92.0–140.0) 110.0 (89.0–134.0) <0.01
Dyslipidemia (%) 5325 (54.6) 9294 (61.5) <0.01
Reduced HDL Cholesterol
HDL-Cholesterol (mg/dL)b 53.7 (16.0) 50.8 (16.1) <0.01
Elevated Blood Pressure
DBP (mmHg)b 78.6 (10.1) 75.2 (9.2) <0.01
SBP (mmHg)b 130.7 (17.3) 125.4 (15.9) <0.01
Hypertension (%) 6965 (71.0) 7638 (50.3) <0.01
Elevated Fasting Glucose
Insulin (uU/mL)c 10.9 (6.8–17.2) 8.8 (5.6–13.8) <0.01
Fasting glucose (mg/dL)b 107.0 (38.9) 99.4 (26.9) <0.01
Diabetes (%) 2873 (29.4) 2460 (16.2) <0.01
Metabolic Components d(%)
0 642 (6.5) 2193 (14.4) <0.01
1 1910 (19.5) 3577 (23.5)
2 2774 (28.2) 3532 (23.2)
3 2615 (26.6) 2897 (19.0)
4 1482 (15.1) 2041 (13.4)
5 399 (4.1) 976 (6.4)
aSignificance determined using Chi-square test for categorical, ANOVA for continuous, or Kruskal-Wallis test for non-parametric continuous variables
bPresented as mean (standard deviation) for normal continuous characteristics
cPresented as median (interquartile range) for non-parametric continuous characteristics
dMetabolic components are high waist circumference (WC), elevated triglycerides, reduced HDL cholesterol, elevated blood pressure, and elevated fasting glucose
BMI Body Mass Index, HDL high-density lipoprotein, LDL low-density lipoprotein, DBP diastolic blood pressure, SBP systolic blood pressure
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participants with any three (AHR: 1.89, 95% CI: 1.02–3.49),
four (2.44, 95% CI: 1.26–4.74) or five (2.35, 95% CI: 1.01–
5.51) MetS components had a 2-fold increased risk of can-
cer mortality compared with those with none. However,
there were no significant associations between MetS and
risk of cancer morality among White Participants, and
there was no evidence of a statistical interaction on the
multiplicative scale between MetS components and race
(p-values >0.05). Among Black participants, those with re-
duced HDL-cholesterol (AHR: 1.30, 95% CI: 1.02–1.64) and
elevated fasting glucose (AHR: 1.40, 95% CI: 1.09–1.81)
were at an increased risk of cancer mortality. Among White
participants, those with reduced HDL-cholesterol (AHR:
1.27, 95% CI: 1.03–1.55) were at an increased risk of cancer
mortality. The associations between MetS and cancer mor-
tality attenuated in models excluding baseline chronic med-
ical conditions (Additional file 2).
Metabolic dysregulation and cancer mortality
We performed factor analysis and identified six distinct fac-
tors associated with metabolic dysregulation among 19,963
participants with complete data on 15 metabolism-related
Table 2 Hazard ratios (HRs)a and 95% confidence intervals for the association between metabolic syndrome (MetS) and cancer mortality
HR (95% CI)
Black
(N = 402)b
White
(N = 595)b
All
(N = 997)b
p valueinteraction
c
Metabolic Syndrome 1.32 (1.01–1.72) 1.18 (0.94–1.48) 1.22 (1.03–1.45) 0.28
Components
High WC 1.36 (0.75–2.46) 1.32 (0.73–2.36) 1.30 (0.86–1.96) 0.07
Elevated Triglycerides 0.96 (0.71–1.28) 1.04 (0.86–1.25) 1.00 (0.86–1.16) 0.91
Reduced HDL Cholesterol 1.30 (1.02–1.64) 1.27 (1.03–1.55) 1.27 (1.09–1.48) 0.27
Elevated blood pressure 1.43 (0.96–2.15) 0.97 (0.73–1.28) 1.11 (0.89–1.40) 0.89
Elevated fasting glucose 1.40 (1.09–1.81) 1.02 (0.83–1.26) 1.16 (0.99–1.36) 0.57
# Metabolic Syndrome Components
0 (Referent) Referent Referent Referent 0.98
1 1.28 (0.73–2.24) 1.09 (0.78–1.52) 1.15 (0.86–1.53)
2 1.63 (0.92–2.88) 1.07 (0.74–1.54) 1.24 (0.91–1.68)
3 1.89 (1.02–3.49) 1.23 (0.82–1.85) 1.41 (1.01–1.97)
4 2.44 (1.26–4.74) 1.32 (0.84–2.08) 1.62 (1.12–2.34)
5 2.35 (1.01–5.51) 1.36 (0.78–2.38) 1.59 (1.01–2.51)
a Analysis based on 25,038 REGARDS participants with non-missing data on exposure and covariates. Models adjusted for age, sex, race (all model only), education,
region, income, tobacco use, alcohol use, and baseline chronic medical conditions, and hs-CRP
bN = number of cancer death events
c Interaction significance between race*factor (i.e., metabolic syndrome, high waist circumference (WC), and metabolic syndrome components) using Wald test
Bold indicates statistically significant at 0.05 alpha level
Fig. 2 Kaplan-Meier plot for time to cancer death by number of metabolic syndrome components
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variables (Fig. 1 and Additional file 3, previously introduced
in methods). The distribution of each metabolic dysregula-
tion factor by demographic and socioeconomic characteris-
tics of REGARDS participants are provided in Additional
file 4. Among all participants (Table 3 and Additional file
5), those in the highest quartile of the glucose (4th quartile
AHR: 1.35; 95% CI: 1.08–1.61) were at an increased risk of
cancer mortality, while participants in the highest quartiles
for obesity (4th quartile AHR: 0.68; 95% CI: 0.49–0.94) and
cholesterol (3rd vs. 1st quartile AHR: 0.81; 95% CI: 0.65–
Table 3 Hazard ratios (HRs) a and 95% confidence intervals (CIs) for the association between metabolic dysregulation factors and
cancer mortality
Black
(N = 287) b
White
(N = 497) b
All
(N = 784) b
p valueinteraction
c
Obesity
1st Quartile (Ref) Referent Referent Referent 0.25
2nd Quartile 0.69 (0.48–0.98) 0.77 (0.60–0.99) 0.77 (0.62–0.94)
3rd Quartile 0.57 (0.37–0.88) 0.68 (0.50–0.94) 0.72 (0.56–0.93)
4th Quartile 0.63 (0.38–1.06) 0.71 (0.47–1.07) 0.84 (0.61–1.16)
Cholesterol
1st Quartile (Ref) Referent Referent Referent 0.27
2nd Quartile 0.92 (0.66–1.28) 0.68 (0.52–0.88) 0.77 (0.63–0.94)
3rd Quartile 0.76 (0.53–1.09) 0.83 (0.64–1.08) 0.81 (0.65–0.99)
4th Quartile 0.87 (0.61–1.25) 0.86 (0.66–1.13) 0.86 (0.70–1.07)
Blood Pressure
1st Quartile (Ref) Referent Referent Referent 0.55
2nd Quartile 1.02 (0.68–1.54) 1.06 (0.81–1.39) 1.06 (0.85–1.32)
3rd Quartile 0.89 (0.57–1.39) 0.87 (0.63–1.21) 0.89 (0.69–1.16)
4th Quartile 0.78 (0.48–1.25) 0.92 (0.64–1.31) 0.86 (0.65–1.14)
Lipids
1st Quartile (Ref) Referent Referent Referent 0.55
2nd Quartile 1.28 (0.91–1.79) 0.95 (0.70–1.29) 1.07 (0.85–1.33)
3rd Quartile 1.12 (0.73–1.74) 0.92 (0.64–1.33) 1.00 (0.76–1.32)
4th Quartile 1.42 (0.86–2.32) 1.20 (0.81–1.79) 1.30 (0.96–1.77)
Height
1st Quartile (Ref) Referent Referent Referent 0.07
2nd Quartile 0.90 (0.60–1.33) 1.00 (0.74–1.36) 0.97 (0.77–1.23)
3rd Quartile 1.34 (0.89–2.03) 0.86 (0.61–1.23) 1.04 (0.80–1.36)
4th Quartile 0.91 (0.56–1.49) 0.83 (0.56–1.22) 0.88 (0.65–1.19)
Glucose
1st Quartile (Ref) Referent Referent Referent 0.58
2nd Quartile 1.28 (0.88–1.85) 1.20 (0.91–1.58) 1.23 (0.99–1.54)
3rd Quartile 1.15 (0.78–1.68) 1.23 (0.93–1.62) 1.21 (0.97–1.51)
4th Quartile 1.57 (1.10–2.23) 1.21 (0.90–1.62) 1.35 (1.08–1.69)
# Factor Variables in 4th Quartile
0 (Referent) Referent Referent Referent 0.08
1 0.83 (0.56–1.21) 1.60 (1.16–2.19) 1.27 (0.99–1.62)
2 0.92 (0.62–1.36) 1.52 (1.08–2.14) 1.25 (0.97–1.62)
3+ 1.02 (0.65–1.62) 1.39 (0.94–2.07) 1.23 (0.91–1.66)
aAnalysis based on 19,963 REGARDS participants with non-missing data on all factor analysis component variables. Models adjusted for age, sex, race (all model
only), education, region, income, tobacco use, alcohol use, and baseline chronic medical conditions, and hs-CRP
bN = number of cancer death events
c Interaction significance between race*factor using Wald test. Bold indicates statistically significant at 0.05 alpha level
Akinyemiju et al. BMC Cancer  (2017) 17:856 Page 6 of 9
0.99) factors had reduced risk of cancer mortality compared
with those in the first quartile. Black and White participants
within higher quartiles of the obesity factor had a reduced
risk of cancer mortality compared with those in the lowest
quartile, however Blacks in the highest quartile of the glu-
cose factor experienced increased risk (AHR: 1.57; 95% CI:
1.10–2.23) for cancer mortality compared with those in the
first quartile. White participants with one (AHR: 1.60, 95%
CI: 1.16–2.19) or two (AHR: 1.52, 95% CI: 1.08–2.14) of any
factor in the highest quartile were at an increased risk of
cancer mortality. The associations between derived factors
for metabolic dysregulation and cancer mortality were simi-
lar in models excluding baseline chronic medical conditions
(Additional file 6).
Discussion
In a large prospective cohort of community-dwelling adults,
we observed significant differences in the prevalence
of MetS and metabolic dysregulation by race. This study
fills a significant gap in the literature regarding the role of
metabolic dysregulation, defined here using the harmo-
nized MetS criteria as well as factor analysis, in relation to
cancer mortality. Black participants in this study had a
higher prevalence of MetS and dysregulated metabolic
components when compared with White participants.
Overall, participants who met the criteria for MetS were at
significantly higher risk for cancer mortality, and the risk
increased with increasing number of components. Of the
factor analysis-derived metabolic components, elevated glu-
cose levels was strongly associated with increased mortality,
while obesity and high cholesterol were associated with re-
duced cancer mortality. In race-stratified analysis, Blacks
with MetS had about a 2-fold increased risk of cancer mor-
tality compared with those without MetS, however there
were no significant associations among Whites.
The joint harmonized criteria for MetS was developed to
generate consensus regarding the clinical importance and
standardized definition of this condition[20], further stimu-
lating renewed attention into its impact on health out-
comes. The link between individual metabolic components,
i.e. central obesity, insulin resistance, dyslipidemia and
chronic diseases have been known for many decades, al-
though only recently has compelling research studies begun
to emerge on the biological consequence the MetS cluster in
chronic diseases. Metabolic syndrome has been associated
with significantly increased risk of coronary heart disease
and stroke in multiple research studies [2–5]. Furthermore,
individual components of MetS – specifically obesity [6, 7],
diabetes [8], and hypertension [9, 10] – have also been asso-
ciated with increased risk of multiple cancers, and MetS
has been shown to be as a strong risk factor for breast can-
cer, with odds ratios ranging from 2.50 in Brazil, (95% CI:
1.17–5.30) [11], to 6.28 in Italy (95% CI 2.79–14.11) [13].
Strikingly, women with MetS who develop breast cancer
were more than twice as likely to develop distant metastasis
[14], and aggressive tumors [16, 17]. What has remained
less controversial is the inextricable link between poor diet
and obesity with MetS, and an understanding that these
predisposing factors are more prevalent among Blacks com-
pared with Whites- a trend that was observed in this study
and has remained consistent for several decades [25, 26].
The consistent associations observed in this study be-
tween having MetS and increased risk of cancer mortality,
as well as higher risk with increasing number of MetS
components suggests that prevention strategies focused
on these modifiable factors, i.e. obesity, cholesterol, blood
pressure and glucose, are warranted and should be consid-
ered as part of comprehensive cancer control and preven-
tion plans. Unfortunately, past strategies to reduce the
prevalence of MetS risk factors may have had limited suc-
cess due to individual and community level factors such
as poverty, lack of availability of fresh food, safe walking
environments and routine access to preventive care in
many communities [27, 28]. More research will be needed
to better identify race-specific public health strategies that
have the best chance of eliminating individual MetS com-
ponents as well as clinical strategies to control the entire
cluster of MetS, since those strategies may have significant
potential to reduce racial disparities in cancer mortality.
Certain limitations are relevant to the interpretation of
this study. First, although metabolic factors were measured
at baseline prior to cancer diagnosis or mortality, observed
values may have been subject to information biases. Sec-
ond, although we adjusted for confounding due to several
baseline covariates, physical activity variables that may
affect lipid and blood pressure levels were not included in
the analysis. In addition, the total number of cancer deaths
may be underestimated in this population as the REGARDS
study was primarily intended to identify incident stroke
events was not specifically focused on cancer outcomes.
We did not have information regarding cancer stage or
treatment and therefore were unable to make statistical ad-
justments for these differences in our models. We were
likely underpowered due to small sample sizes in the race-
stratified analysis, and were unable to examine cancer-
specific mortality in the present analysis. In particular, given
the follow-up time of 5 to 9 years available in this study,
less fatal cancer types such as breast and prostate cancer,
may have been under-represented in the analysis. However,
we plan future studies that include more years of follow-up
and a wider range of cancer types to support cancer-
specific mortality analysis.
Conclusions
In conclusion, Black participants with MetS at baseline
were at higher risk for cancer mortality during follow-up
compared with those without MetS.
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